AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
NEW YORK, Feb. 21, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Natus Medical Incorporated (NASDAQ:BABY) securities between October 16, 2015 and April 3, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/natus-medical-incorporated. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis.
If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/natus-medical-incorporated.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
